Compared with men with normal prostates, benign prostatic hyperplasia, prostatitis and localized disease, approximately 50% of patients with advanced prostate cancer have increased levels of serum IL-6 (Twillie et al., 1995). Here, IL6 is linked to prostate carcinoma.